Abstract:Alzheimer's disease (AD) is the leading cause of dementia, afflicting 5 million Americans and costing over 200 billion dollars per year. The mechanisms involved in AD pathogenesis are still poorly understood. Moreover, no therapy is available to cure AD or to slow down its progression. The study of new pathways involved in AD pathogenesis is necessary to develop new therapeutic targets. The 12/15-lipoxygenase enzymatic pathway (12/15-LO) is upregulated in postmortem brain tissues and cerebrospinal fluid of AD patients. Its genetic absence or pharmacological inhibition prevents the development of the AD-like phenotype in transgenic mouse models of the disease. However, whether targeting pharmacologically this pathway after the neuropathological lesions and behavioral impairments are well established could be a viable therapeutic strategy against AD remain to be investigated. To this end, 12-month-old triple transgenic mice (3xTg) and their appropriate wild type controls were randomized to receive a specific and selective pharmacological inhibitor of 12/15-LO, PD146176, or placebo. After 3 months, when the animals were 15-month-old, treated and untreated groups were assessed for the effects of the drug on their behavioral impairments and neuropathology. While 15-month-old 3xTg mice on placebo by the end of the study showed a worsening of their memory and learning abilities, as assessed by the fear conditioning paradigms, mice at the same age receiving the PD146176 performed better than baseline in the same test. Compared with placebo, treated mice had significantly less Abeta levels and deposition, improved tau pathology as well as markers of synaptic integrity. Additionally, the same PD146176 treated animals showed a significant upregulation of autophagy markers, suggesting an involvement of this pathway in the pharmacological effect. In vitro experiments demonstrated that 12/15-LO effect on tau metabolism is mediated by modulating neuronal autophagy system. These studies provide new insights into the disease-modifying action of pharmacological inhibiting 12/15-LO as a viable therapeutic approach for AD treatment. They represent the successful completion of the preclinical studies for the development of this class of drug as clinically applicable therapy for the disease.

5-Lipoxygenase Pathway and Its Downstream Cysteinyl Leukotrienes As Potential Therapeutic Targets for Alzheimer’s Disease

The Lipoxygenases: Their Regulation and Implication in Alzheimer’s Disease

Progress on Research of 5-Lipoxygenase in Alzheimer’s Disease

[Cyclooxygenases, Lipoxygenases, Their Targeted Drugs and the Prevention of Alzheimer's Disease].

Effect of intraperitoneal pentobarbital injection or isoflurane inhalation anesthesia on the rat acute stress response

5-Lipoxygenase As an Emerging Target Against Age-Related Brain Disorders

The intricate role of CCL5/CCR5 axis in Alzheimer disease

Cysteinyl Leukotrienes and Their Receptors: Emerging Therapeutic Targets in Central Nervous System Disorders

New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer's disease

Targeting NADPH oxidase and phospholipases A2 in Alzheimer's disease

A Review of Oxylipins in Alzheimer's Disease and Related Dementias (ADRD): Potential Therapeutic Targets for the Modulation of Vascular Tone and Inflammation

Unveiling the role of astrogliosis in Alzheimer's disease Pathology: Insights into mechanisms and therapeutic approaches

P1‐017: 12/15‐lipoxygenase Inhibition Reverses Cognitive Impairment, Amyloidosis, TAU and Synaptic Pathology by Stimulating Autophagy in the Brain of Aged 3XTG Mice

Lysophospholipids and Their G-Coupled Protein Signaling in Alzheimer’s Disease: from Physiological Performance to Pathological Impairment

Leukotriene signaling in neurodegeneration: implications for treatment strategies

12/15-LIPOXYGENASE INHIBITION REVERSES COGNITIVE IMPAIRMENT, AMYLOIDOSIS, TAU AND SYNAPTIC PATHOLOGY BY STIMULATING AUTOPHAGY IN THE BRAIN OF AGED 3XTG MICE

Eicosanoid Signaling in Neuroinflammation Associated with Alzheimer's Disease

Preventive Effect of Genetic Knockdown and Pharmacological Blockade of CysLT1R on Lipopolysaccharide (Lps)-Induced Memory Deficit and Neurotoxicity in Vivo

Prostaglandins and other lipid mediators in Alzheimer's disease

The Kynurenine Pathway, Aryl Hydrocarbon Receptor, and Alzheimer's Disease

Lipid Metabolism and Neuroinflammation in Alzheimer's Disease: A Role for Liver X Receptors